135 related articles for article (PubMed ID: 36521353)
21. Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma.
Nasioudis D; Mulugeta-Gordon L; McMinn E; Byrne M; Ko EM; Cory L; Haggerty AF; Latif NA
Int J Gynecol Cancer; 2021 Mar; 31(3):480-483. PubMed ID: 33649017
[TBL] [Abstract][Full Text] [Related]
22. Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases only.
Grossi E; Noli S; Scarfone G; Villa A; Parazzini F; Cipriani S; Bolis G
Eur J Gynaecol Oncol; 2012; 33(6):615-6. PubMed ID: 23327056
[TBL] [Abstract][Full Text] [Related]
23. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study.
Anuradha S; Webb PM; Blomfield P; Brand AH; Friedlander M; Leung Y; Obermair A; Oehler MK; Quinn M; Steer C; Jordan SJ
Med J Aust; 2014 Sep; 201(5):283-8. PubMed ID: 25163381
[TBL] [Abstract][Full Text] [Related]
24. Evolving population-based statistics for rare epithelial ovarian cancers.
Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
[TBL] [Abstract][Full Text] [Related]
25. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
26. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?
Chan JK; Loizzi V; Lin YG; Osann K; Brewster WR; DiSaia PJ
Obstet Gynecol; 2003 Jul; 102(1):156-61. PubMed ID: 12850623
[TBL] [Abstract][Full Text] [Related]
27. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data.
Davis FG; McCarthy BJ; Freels S; Kupelian V; Bondy ML
Cancer; 1999 Jan; 85(2):485-91. PubMed ID: 10023719
[TBL] [Abstract][Full Text] [Related]
28. Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery.
Nasioudis D; Wang X; Dhillon G; Latif N; Ko EM; Giuntoli RL; Gershenson D; Fader A; Carey M; Simpkins F
Int J Gynecol Cancer; 2023 Dec; 33(12):1906-1912. PubMed ID: 37879909
[TBL] [Abstract][Full Text] [Related]
29. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
Fujiwara K; Sakuragi N; Suzuki S; Yoshida N; Maehata K; Nishiya M; Koshida T; Sawai H; Aotani E; Kohno I
Gynecol Oncol; 2003 Sep; 90(3):637-43. PubMed ID: 13678738
[TBL] [Abstract][Full Text] [Related]
30. Long-term oncologic outcome and its prognostic indicators in reproductive-age women with ovarian clear-cell carcinoma.
Kajiyama H; Suzuki S; Yoshikawa N; Niimi K; Kawai M; Shibata K; Kikkawa F
Arch Gynecol Obstet; 2019 Sep; 300(3):717-724. PubMed ID: 31165243
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
33. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
34. Does complete-staging lymphadenectomy improve survival outcomes in stage I endometrioid epithelial ovarian carcinoma? A multi-institutional retrospective study with propensity score-weighted analysis.
Yoshihara M; Tamauchi S; Iyoshi S; Kitami K; Uno K; Tano S; Matsui S; Kajiyama H
Jpn J Clin Oncol; 2021 Mar; 51(3):387-392. PubMed ID: 33253382
[TBL] [Abstract][Full Text] [Related]
35. Ten-year relative survival for epithelial ovarian cancer.
Baldwin LA; Huang B; Miller RW; Tucker T; Goodrich ST; Podzielinski I; DeSimone CP; Ueland FR; van Nagell JR; Seamon LG
Obstet Gynecol; 2012 Sep; 120(3):612-8. PubMed ID: 22914471
[TBL] [Abstract][Full Text] [Related]
36. Conditional disease-free survival rates and their associated determinants in patients with epithelial ovarian cancer: A 15-year retrospective cohort study.
Ebrahimi V; Khalafi-Nezhad A; Ahmadpour F; Jowkar Z
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1416. PubMed ID: 33949809
[TBL] [Abstract][Full Text] [Related]
37. Survival probability in ovarian clear cell adenocarcinoma.
Kennedy AW; Markman M; Biscotti CV; Emery JD; Rybicki LA
Gynecol Oncol; 1999 Jul; 74(1):108-14. PubMed ID: 10385560
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
40. Conditional survival analysis for patients with intraductal papillary mucinous neoplasms (IPMNs) undergoing curative resection.
Gaitanidis A; Alevizakos M; Tsaroucha A; Tsalikidis C; Simopoulos C; Pitiakoudis M
Eur J Surg Oncol; 2018 May; 44(5):693-699. PubMed ID: 29426780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
